Scholars@Duke
Angeles Alvarez Secord

Angeles Alvarez Secord

Professor of Obstetrics and Gynecology
Obstetrics and Gynecology, Gynecologic Oncology
secor002@mc.duke.edu
Box 3079 Med Ctr, Durham, NC 27710
25172 Morris Bldg, Durham, NC 27710

Scholarly Works - Conferences

Addressing barriers to FRα-directed therapy integration in platinum-resistant ovarian cancer: A multi-phase, community-informed initiative.

Conference Journal of Clinical Oncology · June 1, 2026 5601Background: Antibody–drug conjugates (ADCs) targeting folate receptor alpha (FRα) ... Full text Cite

Azenosertib plus paclitaxel for platinum-resistant ovarian cancer: Results from a phase 1b study.

Conference Journal of Clinical Oncology · June 1, 2026 5529Background: Most patients (pts) with ovarian cancer develop platinum-resistant di ... Full text Cite

Abstract B013: Cyclin E1 Positive Protein Status is a Predictive Biomarker of Azenosertib Benefit in Platinum-Resistant Ovarian Cancer: Part 2 of the DENALI Study (GOG-3066)

Conference Molecular Cancer Therapeutics · October 22, 2025 AbstractBackground:Cyclin E1 positive protein expression comprises a significant portion of patients with platinum resistant ov ... Full text Cite

A phase 3, open-label, randomized study of rinatabart sesutecan (Rina-S) vs investigator’s choice (IC) of chemotherapy in patients with platinum-resistant ovarian cancer (PROC).

Conference Journal of Clinical Oncology · June 2025 TPS5627Background: Ovarian cancer (OC) is the fifth leading cause of cancer-related death among women in the United States, w ... Full text Cite

Abstract 4195: Efficacy of tumor treating fields (TTFields) applied with cisplatin and paclitaxel in cervical cancer cells

Conference Cancer Research · April 21, 2025 AbstractIntroduction:Most cervical cancer patients with advanced disease receive first-line cisplatin-based chemotherapy. For late-sta ... Full text Cite

Tumor Treating Fields (TTFields) Augment the Efficacy of Cisplatin for Treatment of Cervical Cancer, In Vitro and In Vivo

Conference INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS · October 1, 2024 Link to item Cite

Abstract 7219: Preclinical investigations of concomitant tumor treating fields (TTFields) with cisplatin for treatment of cervical cancer

Conference Cancer Research · March 22, 2024 AbstractIntroduction: Cervical cancer, although largely preventable, continues to be a significant health concern. Early-stage treatment is commonly surgery; while advanced, recurrent, or metastatic disease ... Full text Cite

Abstract B028: Preclinical effects of Tumor Treating Fields (TTFields) applied with cisplatin for treatment of cervical cancer

Conference Cancer Research · January 9, 2024 AbstractIntroduction: Though largely preventable, cervical cancer remains a significant health issue. Treatment of early-stage disease usually involves surgery; while systemic therapy is often required for a ... Full text Cite

Phase 2, single arm clinical trial to evaluate the safety and activity of oregovomab and niraparib as a combinatorial immune priming strategy in subjects with platinum sensitive recurrent ovarian cancer: FLORA-4 study.

Conference Journal of Clinical Oncology · January 1, 2024 Background: Oregovomab, a murine IgGκ1 MAb, with high affinity binding (1.16 x 1010/M−1) to the tumor associated antigen CA125 acts as a therapeutic vaccine inducing indirect immunization by cellular and humoral immune responses directed against CA125. We ... Full text Cite

FLORA-5/GOG3035: Chemo-immunotherapy (paclitaxel-carboplatin-oregovomab [PCO] vs chemotherapy (paclitaxel-carboplatin-placebo [PCP]) as front-line treatment in patients with advanced epithelial ovarian cancer (EOC)—Phase III, double blind, placebo controlled, global, multinational study.

Conference Journal of Clinical Oncology · June 1, 2023 TPS5625 Background: Oregovomab, a murine IgGκ1 monoclonal antibody with high affinity binding to tumor associated antigen CA125, renders the target antigen CA125 more immunogenic or “neoantigen-like”. The proposed mechanism actio ... Full text Cite

Randomized controlled phase III trial of weekly paclitaxel ± ofranergene obadenovec (VB-111) for platinum-resistant ovarian cancer (OVAL Study/GOG 3018).

Conference Journal of Clinical Oncology · June 1, 2023 5505 Background: Ofranergene obadenovec (ofra-vec, VB-111) is a nonreplicating adenoviral vector with a murine pro-endothelin 1 (PPE-1-3X) promoter and pro-apoptotic Fas-tumor necrosis factor receptor 1 (TNFR1) chimeric transgene ... Full text Cite

Abstract 2666: Preclinical investigations of concomitant tumor treating fields (TTFields) with cisplatin or paclitaxel for treatment of cervical cancer

Conference Cancer Research · April 4, 2023 AbstractIntroduction: Cervical cancer is a serious health problem despite the fact it is highly preventable. Early-stage cervical cancer treatment often involves surgery; however advanced, recurrent, or meta ... Full text Cite

LIO-1: Lucitanib + nivolumab in patients with advanced solid tumors—Updated phase 1b results and initial experience in phase 2 ovarian cancer cohort.

Conference Journal of Clinical Oncology · May 20, 2021 5538 Background: The phase (Ph) 1b part of LIO-1 (NCT04042116; ENGOT-GYN3/AGO/LIO) assessed the oral antiangiogenic, multikinase inhibitor lucitanib + immune checkpoint inhibitor nivolumab, confirming the recommended Ph2 dose (RP ... Full text Cite

Clinical trial in progress: Pivotal study of VB-111 combined with paclitaxel versus paclitaxel for treatment of platinum-resistant ovarian cancer (OVAL, VB-111-701/GOG-3018).

Conference Journal of Clinical Oncology · May 20, 2021 TPS5599 Background: Ofranergene obadenovec (VB-111) is a targeted anti-cancer gene therapy with a dual mechanism of action that includes a broad antiangiogenic effect and induction of a tumor directed immune response. A phase II ... Full text Cite

A phase 3, randomized, double-blind, adaptive, placebo/paclitaxel-controlled study of AVB-S6-500 in combination with paclitaxel in patients with platinum-resistant recurrent ovarian cancer (GOG-3059/ENGOT OV-66/AVB500-OC-004).

Conference Journal of Clinical Oncology · May 20, 2021 TPS5605 Background: The AXL receptor and its activating ligand, GAS6, are important drivers of metastasis and therapeutic resistance in human cancers. This signaling axis represents an attractive target for therapeutic interventi ... Full text Cite

FLORA-5: Front-line chemoimmunotherapy (Paclitaxel-Carboplatin-Oregovomab [PCO] versus chemotherapy (Paclitaxel-Carboplatin-Placebo [PCP]) in patients with advanced epithelial ovarian cancer (EOC)—Phase III double-blind placebo controlled multinational study.

Conference Journal of Clinical Oncology · May 20, 2021 TPS5606 Background: Oregovomab binds tumor-associated CA125 rendering the target antigen CA125 more immunogenic or “neoantigen-like” through altered and enhanced antigen processing and presentation to specific T cells. This pheno ... Full text Cite

MnTnBuOE-2-PyP5+ Ascorbate in the Treatment of Ovarian Cancer

Conference Free Radical Biology and Medicine · November 2020 Full text Cite

Patient preferences for maintenance PARP therapy in ovarian cancer treatment.

Conference Journal of Clinical Oncology · May 20, 2019 5558 Background: Maintenance therapy with PARP inhibitors has become prevalent in treating ovarian cancer. However, the preferences of women with ovarian cancer regarding the risks, side effects and benefits afforded by maintenan ... Full text Cite

Management of high, moderate, and low penetrance ovarian cancer susceptibility gene mutations: An assessment of current practice patterns.

Conference Journal of Clinical Oncology · May 20, 2019 1536 Background: Limited information exists regarding appropriate risk-reduction strategies for women with moderate and low penetrance ovarian cancer (OVCA) susceptibility mutations. We sought to assess current practice patterns ... Full text Cite

AtTEnd/ENGOT-en7: A multicenter phase III double-blind randomized controlled trial of atezolizumab in combination with paclitaxel and carboplatin in women with advanced/recurrent endometrial cancer.

Conference Journal of Clinical Oncology · May 20, 2019 TPS5608 Background: Prognosis of advanced/recurrent endometrial cancer (EC) is poor with median survival of 12-15 months for patients with measurable disease. Treatment options are limited, with primary management being chemother ... Full text Cite

Bevacizumab beyond progression: Impact of subsequent bevacizumab retreatment in patients with ovarian, fallopian tube, and peritoneal cancer after progression.

Conference Journal of Clinical Oncology · May 20, 2019 5557 Background: The Food and Drug Administration approved the use of bevacizumab for treatment of recurrent epithelial ovarian, fallopian tube, and primary peritoneal carcinoma (OC) in combination with chemotherapy. This study e ... Full text Cite

A randomized phase 3 trial of paclitaxel (P) plus carboplatin (C) versus paclitaxel plus ifosfamide (I) in chemotherapy-naive patients with stage I-IV, persistent or recurrent carcinosarcoma of the uterus or ovary: An NRG Oncology trial.

Conference Journal of Clinical Oncology · May 20, 2019 5500 Background: Gynecologic carcinosarcomas (CS) are rare yet aggressive epithelial malignancies for which optimal therapy is debated. PI was shown to be superior to I. PC demonstrated compelling phase 2 activity with improved s ... Full text Cite

Uterine Vascular Embolization Followed by Hysterectomy After Cesarean for MAP Without Extrauterine Involvement [32T]

Conference Obstetrics & Gynecology · May 2019 INTRODUCTION:To review outcomes in women with morbidly adherent placenta (MAP) managed with selective uterine vasculature embolization (SUVE) at the time of cesarean hysterectomy (CHYS).< ... Full text Cite

Mn porphyrin/ascorbate sensitizes serous epithelial ovarian cancer to chemotherapy

Conference Free Radical Biology and Medicine · November 2018 Full text Cite

GOG213

Conference INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER · September 1, 2018 Link to item Cite

PHASE 2 TRIAL OF WEEKLY PACLITAXEL WITH PEMBROLIZUMAB IN PLATINUM RESISTANT RECURRENT OVARIAN CANCER

Conference INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER · September 2018 Link to item Cite

Management of platinum-sensitive recurrent ovarian cancer (PSROC) in the era of biologics: Can ASCO’s net health benefits (NHB) inform our decisions?

Conference Journal of Clinical Oncology · May 20, 2017 5544 Background: The ASCO value framework allows assessment of novel cancer therapies based on NHB. We assessed novel biologic therapies in the management of PSROC. Methods: ASCO’s revised value framework NHBs were constructed fo ... Full text Cite

Evaluating the repertoire of immune checkpoint markers expressed on peripheral and ascites CD8+ T cells in ovarian cancer.

Conference Journal of Clinical Oncology · May 20, 2017 5571 Background: Understanding the immune checkpoint marker repertoire can facilitate development of therapeutic strategies to improve efficacy of immune-based therapies. We used a novel high-dimensional flow cytometry panel to d ... Full text Cite

A randomized phase II evaluation of weekly gemcitabine plus pazopanib versus weekly gemictabine alone in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma.

Conference Journal of Clinical Oncology · May 20, 2017 5532 Background: Inhibition of angiogenesis is a valuable treatment strategy for ovarian cancer. Pazopanib (paz) is a potent angiogenic small molecular inhibitor of the tyrosine kinases VEGRF-1, -2, -3, PDGFR, c-kit and has shown ... Full text Cite

Vaginal cuff thermal injury by mode of colpotomy at total laparoscopic hysterectomy: a randomized clinical trial.

Conference J Minim Invasive Gynecol · February 2015 STUDY OBJECTIVE: To evaluate if the use of Valleylab mode ("V mode") (Covidien, Mansfield, MA) electrothermal energy for colpotomy during total laparoscopic hysterectomy (LH) results in a smaller margin of thermal injury to the upper vagina compared with t ... Full text Link to item Cite

Abstract 2320: Clinical epigenetic resensitization of platinum-resistant, recurrent ovarian cancer patients with SGI-110, a novel, second-generation, subcutaneously administered hypomethylating agent (HMA)

Conference Cancer Research · October 1, 2014 AbstractBackground: Epigenetic changes have been implicated in acquired resistance to platinum. SGI-110 is a second generation SQ HMA with improved pharmaceutical properties compared to decitabine. Here we r ... Full text Cite

The impact of diabetes and obesity on endometrial cancer outcomes

Conference JOURNAL OF CLINICAL ONCOLOGY · May 20, 2013 Link to item Cite

Abstract 330A: Differential expression of angiogenic genes in invasive high grade serous ovarian carcinomas.

Conference Cancer Research · April 15, 2013 AbstractOur objective is to establish quantifiable and reproducible biomarkers that can aid in prognosis, and predicting treatment outcome in invasive high-grade serous ovarian cancer (HGSC). The goal of thi ... Full text Cite

Effect of treatment of patients with early-stage uterine carcinosarcoma

Conference JOURNAL OF CLINICAL ONCOLOGY · May 20, 2009 Link to item Cite

68

Conference International Journal of Radiation Oncology*Biology*Physics · November 2006 Full text Cite

Tissue transglutaminase expression in early-stage cervical cancer

Conference INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS · 2006 Full text Link to item Cite